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Abstract
Objective: Aim of study was to evaluate safety and efﬁcacy of abluminal Mitigator DES þ Sirolimus Eluting Stent
(Envision Scientiﬁc, Surat, India) incorporating novel technology of fusion coating of bioresorbable polymer on both
abluminal surface of stent and exposed parts of balloon among real world patients specially focusing younger patients
(<35 years).
Method: 1293 patients received Mitigator DES þ at LPS Institute of Cardiology, Kanpur, India. Primary outcome was
target lesion failure (TLF)- composite of cardiovascular death, target vessel myocardial infarction (TVMI), and target
lesion revascularization (TLR) and secondary end points including peri-procedural device failure (failure of stent delivery, change of stent, stent fracture), target vessel failure (TVF), and patient oriented composite end point (POCE)composite of all deaths, MI, and revascularization and stent thrombosis (ST) at 1-year follow-up.
Result: Younger population comprised of 374 (29%) patients. Various indications of interventions were STEMI
(n ¼ 614; 47.4%), NSTEMI (n ¼ 416; 32.2%), UA (n ¼ 161; 12.5%), and CCS (n ¼ 102; 7.9%). TLF at 1 year in young and
overall population were 3.4% and 3.5% respectively which was driven by TVMI and TLR in 1.3% and 1.1% patients
respectively. POCE was observed in 9.5% in each group mainly contributed by any revascularization (3.9%). Device
failure was signiﬁcantly lower in young group than overall population (1.3% vs. 2.2%; p ¼ 0.04) which was mainly driven
by stent delivery (1.1%) and edge dissection (0.5%). Deﬁnite and probable ST was 1.3% and 1.7% respectively which was
not signiﬁcant. Young patients showed insigniﬁcantly lower TLF, TVF, ST and POCE and signiﬁcantly lower device
failure (1.3% vs. 2.6%; p ¼ 0.04) when compared to patients >35 years. On multivariate regression analysis, complex
lesion, in-stent restenosis, failure of stent delivery and edge dissection were independent predictors of events or device
success rate.
Conclusion: Mitigator DESþ™ is safe among real world patients, including young population.
Keywords: Drug-eluting stent, Target lesion failure, Patient oriented composite end point, Stent thrombosis, Percutaneous coronary intervention

1. Introduction

W

ith the improvement in hardwares and
availability of imaging modalities like
intravascular ultrasound and optical coherence

tomography, PCI is frequently being performed of
diffuse, calciﬁed and other complex lesions. Earlier
generation of DES were shorter in length and had
thicker struts (120 mm), thus making them less
trackable and deliverable across the lesion which
were subsequently replaced by stents having
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thinner stent strut with biodegradable polymer [1].
Compared to the previous generation of drug
eluting stent (DES), the current one have shown to
provide a better efﬁcacy/safety proﬁle in the treatment of simple as well as complex coronary disease
by means of percutaneous coronary angioplasty
(PCI). Nevertheless, those proved results are still
suboptimal for speciﬁc subset of high-risk patients,
particularly for diabetic patients and those having
small vessel involvement as they are associated with
worse outcomes following PCI. The design of typical
DES consists of metallic platform and drug polymer
(biodegradable/biostable). Durable polymer is
associated with very late stent thrombosis, delayed
arterial healing and neoatherosclerosis. Restenosis
rate is higher among diabetic patients especially
those having diffuse and long lesions affecting small
vessel (2.75 mm) [2,3]. These are quite common
among Indian population where small vessel afﬂiction is seen in nearly 30%e50% of patients with
coronary artery disease. It spurred the introduction
of new generations of DES which were theoretically
able to circumvent these issue. The primary objective was to assess efﬁcacy and safety of Mitigator
DES þ Sirolimus eluting stents (Envision Scientiﬁc,
Surat, India) among real world patients including
younger patients (<35 years) as they have different
clinicoeangiographic proﬁle compared with older
population (>35 years). With its unique features it
might provide better short as well as long-term
outcomes among these subset of population as they
constitute signiﬁcant proportion in India.

2. Material and method
2.1. Study design and participants
This was a prospective and observational study
conducted between July 2017 and October 2018 at
LPS Institute of Cardiology, Kanpur, India among
all comer patients who received Mitigator DESþ.
Revascularization was based on current guideline.
Patients presenting with acute coronary syndrome
and chronic coronary syndrome who were refractory to optimal medical treatment were
included. Patients younger than <18 years, pregnant
women, intolerance to aspirin, P2Y12 inhibitor
(clopidogrel, ticagrelor, prasugrel) or sirolimus,
anticipated major surgery within 6-months
following PCI, life expectancy <12 months, and
having cardiogenic shock were excluded.
Baseline demographics of patients and procedural
detail including angiographic ﬁndings were recorded. They were categorized as young group (<35
years) and old group (>35 years). Lesion was

Abbreviations
PCI
DES
DEB
DAPT
ACS
CCS
MI
TLF
TVMI
TLR
TVR
ST
POCE
ARC
CAD

Percutaneous coronary intervention
Drug eluting stent
drug eluting balloon
Dual antiplatelet
Acute coronary syndrome
Chronic coronary syndrome
Myocardial infarction
Target lesion failure
Target vessel myocardial infarction
Target lesion revascularization
Target vessel revascularization
Stent thrombosis
Patient-oriented composite endpoint
Academic Research Consortium
Coronary artery disease

classiﬁed as type A, B1/B2, C [1]. Procedures were
performed after obtaining signed informed consent
from all patients. The study was conducted in
accordance with Declaration of Helsinki and protocol was approved by institutional ethical committee.
2.2. Study device description
Mitigator DES belongs to Abluminous family of
stents consisting of device platform and drug
product. Device platform is made from L-605 cobalt
chromium alloy having opposite alignment
connector having open cells in mid segment and
closed cells at both ends imparts it a hybrid design.
Peak to peak strut alignment facilitates adequate
scaffolding which reduces plaque prolapse and ensures optimal metal to artery ratio. Drug product is
combination of sirolimus and biodegradable polymer. It has unique and only technology available
among all contemporary DES i.e fusion coating
(coating on abluminal surface of stent as well as
exposed parts of balloon) by which it offers dual
advantage of DES as well as DEB (Fig. 1). It ensures
homogeneous drug delivery, faster re-endothelialisation while additional 0.5 mm coating at both edges
helps to prevent edge restenosis. It elutes 50%
sirolimus within one week and 66% within 7-weeks.
Polymer completely degrades over 6 months [4].
2.3. Procedure
PCI was performed following standard technique
using unfractionated heparin as anticoagulant on
weight based dosing (70e100 U/kg). All patients
were pre-treated with aspirin and P2Y12 inhibitor
and DAPT was continued for at least 1-year followed by aspirin monotherapy indeﬁnitely. Minimum stent inﬂation time while deployment was
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Fig. 1. Schematic representation of strut and polymer thickness of contemporary stents (green colour indicates thickness of polymer; Lum-luminal,
Abl-Abluminal; A represents Mitigator DES).

kept 30 s to attain proper conformation of stent and
uniform drug-polymer coating across the lesion [5].
Cardiac biomarkers (CK-MB, troponin- I) were
measured within 8-h following PCI to diagnose
periprocedural MI. Patients were followed clinically
at 1 week, 1,3,6,9 and 12 months.
2.4. Study endpoints
Primary endpoint was TLF at 12 months which
was composite of cardiac death, TVMI, and ischemia
driven TLR. Secondary endpoints included any
death, any revascularization, ischemia-driven TVR,
ST, periprocedural and spontaneous MI, and device
failure (composite of failure of stent delivery, change
of stent, and stent fracture). POCE was deﬁned as
composite of all-cause death, any MI, and any
revascularization. ST, periprocedural, and spontaneous MI were deﬁned according to academic
research consortium criteria [6]. Target vesselrelated MI was attributed to either target vessel or
could not be related to another vessel on basis of
clinical, ECG, echocardiographic, and angiographic
ﬁndings. Device success was deﬁned as successful
trackibility, delivery and deployment of stent at
target lesion with ﬁnal residual stenosis 30%.

2.5. Statistical evaluation
Statistical analyses were performed using SPSS
19.0 (SPSS Inc., Chicago, IL, USA). Categorical variables were expressed as number and percentages
and were compared using Pearson's c2 test or
Fisher's Exact Test. Continuous variables were
described as mean ± SD and compared using t-test
or ManneWhitney Test as appropriate. Survival
analyses and time-to-event outcomes were performed graphically with Kaplan Meier Curve, and
mathematically with the log-rank test. P value of
0.05 was considered as statistically signiﬁcance.

3. Results
3.1. Baseline demographics and clinical
presentation (Table 1)
Nearly 4500 patients underwent revascularization
during index period of which 1293 patients received
Mitigator of which 1196 (92.3%) patients completed
follow up (Fig. 2). However, type of stent selection was
left to operator discretion and on site availability.
There was no particular selection bias for this stent as
this was an observational study among all comer
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Table 1. Baseline demographics and clinical presentation of patients (N ¼ 1293).
Variables

Total patients
n (%)

Young Group
(35 yrs) n (%)

Not Young Group
(35 yrs) n (%)

P
value

N
Age (years)
Male
Female
Serum creatinine (mg/dL)
CAD risk factors
Hypertension
Diabetes mellitus
Smokers
Family history of CAD
Dyslipidemia
Post CABG
Clinical Presentation
STEMI
NSTEMI
UA
CCS
LVEF (%)
a. >55
a. 45-55
b. 35-45
c. <35
Medications
Tenecteplase
Streptokinase
Aspirin
Ticagrelor
Prasugrel
Clopidogrel
Statin
Beta-blocker
ACEI/ARB
CCB
Aldosterone antagonist
Angiographic severity
1. SVD
2. DVD
3. TVD
Location of target vessel
a. LMCA
b. LAD
c. LCx
d. RCA
e. SVG- OM
f. SVG-PDA

1293
51.1 ± 17.5
1027 (79%)
276 (21%)
1.2 ± 0.6

374
32.2 ± 3.2
333 (89%)
41 (11%)
1.1 ± 0.3

919
58.4 ± 10.3
694 (76%)
225 (24%)
1.3 ± 0.7

0.04
0.03
0.4

303 (23.4%)
357 (27.5.4%)
281 (21.6%)
45 (3.3%)
330 (25.8%)
44 (2.2%)

44 (11.8%)
96 (25.7%)
131 (35.2%)
21 (5.6%)
83 (22.2%)
04 (1.1%)

259 (28.2%)
261 (28.4%)
150 (16.3%)
24 (2.6%)
247 (26.9%)
40 (4.3%)

0.03
0.6
0.05
0.05
0.03
0.03

614
416
161
102

(47.4%)
(32.2%)
(12.5%)
(7.9%)

247 (66%)
71 (18.9%)
37 (9.8%)
19 (5.1%)

367 (39.9%)
345 (37.5%)
124 (13.4%)
83 (9%)

0.03
0.04
0.04
0.03

78 (6.1%)
887 (68.5%)
172 (13.3%)
156 (12.1%)

21 (5.6%)
254 (67%)
60 (16%)
39 (10.4%)

57 (6.2%)
78 (68.9%)
112 (12.2%)
117 (12.7%)

0.2
0.4
0.4
0.5

209 (16.1%)
96 (7.4%)
1275 (98.6%)
885 (68.5%)
204 (15.7%)
206 (15.9%)
1257 (97.2%)
960 (74.3%)
1062 (82.1%)
173 (13.3%)
202 (15.6%)

79 (21.1%)
29 (7.7%)
371 (99.1%)
259 (69.2%)
60 (16%)
53 (14.2%)
368 (98.4%)
280 (75%)
311 (83.2%)
44 (11.8%)
57 (15.2%)

130 (14.1%)
67 (7.3%)
904 (98.4%)
626 (68.1%)
144 (15.7%)
153 (16.6%)
889 (96.7%)
680 (73.3%)
751 (81.7%)
129 (14%)
145 (15.7%)

0.2
0.6
0.8
0.7
0.3
0.4
0.4
0.6
0.6
0.5
0.2

919 (71.1%)
237 (18.3%)
137 (9.6%)

289 (77.3%)
57 (15.2%)
28 (7.5%)

630 (68.6%)
180 (19.5%)
109 (11.9%)

0.04
0.05
0.02

77 (5.9%)
635 (49.2%)
184 (14.3%)
369 (28.5%)
12 (0.9%)
16 (1.2%)

19 (5.1%)
230 (61.5%)
87 (23.2%)
147 (39.3%)
00 (00%)
04 (1.1%)

58 (6.3%)
570 (62.3%)
270 (29.3%)
395 (42.9%)
12 (1.3%)
12 (1.3%)

0.6
0.7
0.5
0.4
0.02
0.02

CAD- Coronary artery disease; DM- Diabetes mellitus; CABG- Coronary artery bypass graft; PCI-Percutaneous Coronary Intervention;
STEMI-ST Segment Elevation Myocardial Infarction; NSTEMI-Non ST Segment Elevation Myocardial Infarction; UA-Unstable Angina;
CCS- Chronic Coronary Syndrome; LVEF- Left ventricular ejection fraction; ACEI- Angiotensin-converting enzyme inhibitor; ARBAngiotensin-receptor blocker; CCB- Calcium-channel blocker; SVD-Single vessel disease; DVD- Double-vessel disease; TVD- Triplevessel disease; LAD- Left anterior descending coronary artery; LCx- Left circumﬂex coronary artery; RCA- Right coronary artery; SVGSaphenous vein graft; OM- Obtuse marginal branch; PDA- Posterior descending artery.

patients. They were analyzed according to young
(<35 years) and older adult (>35 years). Younger
group had signiﬁcantly higher proportion of male
patients, smoking, family history of premature CAD
while lesser proportion of female, hypertension,
dyslipidemia, and CABG. STEMI was signiﬁcantly
higher in them with while NSTEMI, UA, and CCS
were signiﬁcantly less. On angiogram, they had

signiﬁcantly higher number of SVD while DVD, TVD
and graft vessel involvement were less.
3.2. Procedural details (Table 2)
Older adults had signiﬁcantly higher number of
complex lesion, CTO, bifurcation lesion, calciﬁed
lesion, and in-stent restenosis than younger group.
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Fig. 2. Flow chart of all patients enrolled in the study (N ¼ 1293).

They also had signiﬁcantly more number of lesions,
and stents per patient.
3.3. Clinical outcomes (Table 3)
TLF was observed in 46(3.5%) among total subjects with non signiﬁcant intergroup difference
though TVMI, TLR, and TVR were relatively lower
among younger group (Fig. 3). Stent failure was
signiﬁcantly higher in older group because of failure
to deliver the stent at target lesion. TVF and POCE
were observed in 60(4.6%) and 124(9.5%) of patients
respectively with non signiﬁcant intergroup difference. On multivariate regression analysis, complex
lesion, ISR, failure of stent delivery and edge
dissection were independent predictors of events or
device success rate (Table 4). Deﬁnite and probable
ST was observed among 13(1%) and 10(0.8%) patients in overall population with non signiﬁcant
intergroup difference (Fig. 4). Late ST (44%)
accounted for majority of stent thrombosis. Figure 5
illustrates KaplaneMeier survival curves of total
patients over 12 month period and outcome was
better in younger group than older group (Fig. 6). Of
all deaths (n ¼ 35; 2.75%), non-cardiac conditions

(eg, stroke, malignancy, renal failure, sepsis, and
pneumonia) attributed for 20(1.6%) deaths while
cardiac deaths 15(1.1%) were attributed to ST (n ¼ 3;
20%), heart failure (n ¼ 5; 33%), MI (n ¼ 4; 26%), and
arrhythmias (n ¼ 3; 20%).

4. Discussion
Age cut-off for ‘‘young population’’ in context of
premature CAD is variable (< 35 to < 55 years) due
to lack of universally accepted cut-off [7]. Although
incidence of MI in younger population may appear
relatively low, 20% of subjects younger than 35 years
had an unexpectedly high prevalence of CHD [8].
Angiographic ﬁndings too differ between
group < 35 years and > 35 years. Based on these
ﬁndings, we decided to choose < 35 years as cut-off
as burden of this relatively young population is
large in India.
Younger population in India has higher predilection for CAD because of dyslipidemia (high triglyceride, low HDL and normal or slightly raised LDL),
diabetes, metabolic syndrome, smoking and stressful
lifestyle. Need of repeat revascularisation (50% at 4.7
years) is relatively higher among younger population
because of longer expected survival [9,10].
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Table 2. Procedural characteristics of patients (N ¼ 1293).
Variables

Total patients
(N ¼ 1293)

Young Group
<35 yrs (N ¼ 374)

Not Young Group
<35 yrs (N ¼ 919)

P
value

Transfemoral Intervention
Transradial Intervention
Size of vessel
a. 2.25e2.5
b. 2.5e3
c. 3e3.5
d. 3.5e4
e. > 4
Lesion characteristics
a. At least 1 complex lesion
b. At least 1 bifurcation lesion
c. At least 1 CTO
d. At least 1 ostial lesion
e. At least 1 calciﬁed lesion
f. In-stent restenosis (ISR)
Lesions per patient
Lesion length (mm)
Lesion Modiﬁcation
a. Direct Stenting
b. Semicompliant balloon
c. Cutting Balloon
Stent Delivery
a. Unassisted
b. Buddy Wire
c. GuideZilla mother-in-child system
Median Stent length per patient (mm)
Full Metal Jacketing (60 mm)
Stent diameter (mm)
Thrombosuction
GP IIb/IIIa inhibitor
Implantation of assigned stents only

1004 (77.4%)
289 (22.6%)

279 (74.6%)
95 (25%)

819 (78.9%)
194 (21%)

0.4
0.5
0.5

211 (16.3%)
250 (19.3%)
571 (44.2%)
208 (16.1%)
53 (4.1%)

57 (15.3%)
76 (20.3%)
160 (42.8%)
64 (17.1%)
17 (4.5%)

154 (16.8%)
174 (18.9%)
411 (44.7%)
144 (15.7%)
36 (3.9%)

862 (66.7%)
132 (10.2%)
171 (13.2%)
59 (4.5%)
57 (4.2%)
29 (2.2%)
1.5 ± 0.2
29 (8e46)

134 (35.8%)
29 (7.8%)
26 (6.9%)
17 (4.5%)
11 (2.9%)
05 (1.3%)
1.4 ± 0.3
21 (12e36)

728 (79.1%)
103 (11.2%)
136 (14.8%)
42 (4.5%)
46 (5%)
24 (2.6%)
1.7 ± 0.4
32 (12e46)

0.04
0.03
0.04
0.5
0.02
0.02
0.03
0.04

166 (12.9%)
1064 (82.3%)
63 (4.8%)

44 (11.7%)
317 (84.4%)
13 (3.4%)

96 (10.4%)
768 (83.6%)
55 (5.9%)

0.6
0.8
0.04

1198 (92.7%)
54 (4.1%)
41 (3.2%)
28 ± 16
99 (7.7%)
2.7 ± 0.3
93 (7.2%)
172 (13.3)
1278 (98.8%)

353 (94.4%)
11 (2.9%)
07 (1.8%)
23 ± 10
23 (6.1%)
2.9 ± 0.5
29 (7.8%)
39 (10.4%)
371 (99.1%)

845 (91.9%)
43 (4.6%)
34 (3.6%)
32 ± 12
76 (8.3%)
2.8 ± 0.4
64 (6.9%)
133 (14.4%)
907 (98.6%)

0.05
0.05
0.04
0.03
0.4
0.5
0.5
0.4
0.5

CTO- Chronic total occlusion; GP- Glycoprotein.

The key ﬁndings in our study were: (a) Mitigator
DES þ is safe and effective among real world patients with acceptable level of clinical event rate
(TLF ¼ 3.5%; deﬁnite ST ¼ 1%) over 12-month
follow-up, (b) rate of CV death, TVMI, and TLR
were 1.3%, 1.1%, and 1.1% respectively and (c)
outcomes were consistent across pre-speciﬁed
groups (  35 years and  35 years).
Male population outnumbered female in our
study as there is a gender bias both in diagnosis,
presentation and mortality. It also showed rural
urban trend as well where proportion of female is
even lesser in rural area [8,11].
Our ﬁndings were not only concordant but
slightly better than reported by Meliga et al. [12]. In
their study, young people were considered < 40
years and only small proportion of them had
received DES and potent antiplatelets. These were
also consistent with event rates reported using
relatively thinner DES (Fig. 1) such as Orsiro SES,
Synergy EES, Resolute ZES [1], Ultimaster [13] and
Biomatrix [14] which reported as 6.7%, 7.5%, 8.3%,
3.4% and 9.2% respectively. The unique design

could have been reason for reduced distal microembolism and slow-ﬂow which are associated with
adverse outcome. When individual components
were analysed, outcome was better among younger
group compared to older in term of cardiac death
and TLR because of lesser complexities of lesion,
CTO and lower median length of stents.
Device success (97.8%) was superior to current
generation stents like Supralimus Cruise (97.6%)
[15], FIREHAWK (92.4%), Xience (94.8%) [16]. Stent
failure was noted in only 1.1% of patients.
Compared to older group, younger group fared
signiﬁcantly better because of lesser number of
complex lesions, CTO, calciﬁed lesion and shorter
stent length. Longer and calciﬁed lesions were
major hinderence to stent delivery. As far as primary outcome, POCE, TVF and other end point was
concerned, periprocedural outcome was not
included in these and hence, had no inﬂuence on
statistical evaluation. Moreover, our study demonstrated that trackability and deliverability might be
an issue among complex lesion like any other DES.
Our ﬁndings were concordant with ﬁndings from

Table 3. Peri-procedural end point and clinical events during 1-year follow-up (N ¼ 1293).
Variables

Overall Patients
(N ¼ 1293)

Young (<35 years)(N ¼ 374)

Not Young (>35 years)(N ¼ 919)

P
value

Target Lesion Failure (TLF)
a. Target vessel MI
b. Ischemia-driven TLR
c. Cardiac death
Device Failure (Secondary)
a. Failure of stent delivery
b. Edge Dissection
c. Stent fracture
d. Coronary perforation
e. Stent dislodgement
Target Vessel Failure (TVF)
POCE
All cause death
Periprocedural MI
Any MI
Any revascularization
Ischemia-driven TVR
Deﬁnite stent thrombosis
a. Acute (0e1 days)
b. Sub-acute (2e30 days)
c. Late (31e360 days)
Probable ST
a. Acute (0e1 days)
b. Sub-acute (2e30 days)
c. Late (31e360 days)
Deﬁnite and Probable ST
a. Acute (0e1 days)
b. Sub-acute (2e30 days)
c. Late (31e360 days)

46 (3.5%)
18 (1.3%)
13 (1.1%)
15 (1.1%)
29 (2.2%)
15 (1.1%)
07 (0.5%)
02 (0.1%)
02 (0.1%)
03 (0.2%)
60 (4.6%)
124 (9.5%)
35 (2.7%)
14 (1.1%)
38 (2.9%)
51 (3.9%)
27 (2.1%)
13 (1%)
05 (0.4%)
06 (0.5%)
02 (0.2%)
10 (0.8%)
02 (0.2%)
04 (0.4%)
04 (0.4%)
23 (1.7%)
07 (0.5%)
10 (0.8%)
06 (0.5%)

13
05
04
04
05
03
01
01
01
01
17
36
10
03
11
13
06
03
02
01
00
02
00
01
01
05
02
02
01

33
13
09
11
24
12
06
01
01
02
43
88
25
11
27
38
21
10
03
05
02
08
02
03
03
18
05
08
05

0.8
0.4
0.5
0.8
0.04
0.02
0.05
0.6
0.7
0.5
0.5
0.7
0.7
0.8
0.7
0.6
0.04
0.6

(3.4%)
(1.3%)
(1.1%)
(1.1%)
(1.3%)
(0.8%)
(0.2%)
(0.2%)
(0.2%)
(0.2%)
(4.5%)
(9.5%)
(2.6%)
(0.8)
(2.8%)
(3.5%)
(1.6%)
(0.8%)
(0.5%)
(0.2%)
(00%)
(0.5%)
(00%)
(0.3%)
(0.2%)
(1.3%)
(0.5%)
(0.5%)
(02%)

(3.5%)
(1.4%)
(1%)
(1.1%)
(2.6%)
(1.3%)
(0.6%)
(0.1%)
(0.1%)
(0.2%)
(4.6%)
(9.6%)
(2.7%)
(1.2%)
(2.2.9%)
(3.8%)
(2.3%)
(1.1%)
(0.3%)
(0.5%)
(0.2%)
(0.8%)
(0.2%)
(0.3%)
(0.3%)
(1.9%)
(0.5%)
(0.8%)
(0.5%)

0.5

0.5

MI- Myocardial infarction; TLR- Target lesion revascularization; TVF-Target vessel failure (composite of cardiac death, target vessel MI,
and ischemia-driven TVR); POCE- Patient-oriented composite endpoint (composite of all-cause death, any MI, and any revascularization); ST- Stent thrombosis; TVR- Target vessel revascularization.

Fig. 3. TLF over 12 months period of follow up between both group (A<35 years; B > 35 years).
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Table 4. Predictors of events or device success rate at 12-months by
multivariate regression analysis (N ¼ 1293).
Variables

Odds Ratio (95% CI)

P-Value

Age
Long lesion
CTO
Median Stent length
Calciﬁed lesion
In stent Restenosis
Failure of stent delivery
Edge Dissection

1.2
3.4
3.8
2.6
6.1
3.1
3.3
2.5

0.6
0.05
0.040
0.05
0.002
0.04
0.04
0.06

(0.8e3.1)
(2.1e8.4)
(2.3e7.9)
(0.9e4.3)
(2.4e15.4)
(1.9e5.2)
(2.1e5.7)
(1.3e4.8)

TALENT trial [16] in which delivery failure was also
considered as outcome but had no interfence on
primary as well as secondary outcome. As far as
sample size was concerned, indeed it was not very
large but at least sufﬁcient enough to draw a
reasonable conclusion. These factors support its
periprocedural safety regarding implantation.
TVF in our study (4.6%) was better than Orsiro
(8.5%), Synergy (8.8%), and Resolute Integrity (10%)
[1], Ultimater (7.4%) [13], Supraﬂex Cruise (5.4%)
[15], Firehawk (9.9%), Xience (9.6%) [16], and Biomatrix [17]. Synergy, Orsiro, Biomatrix and Ultimaster stents have similar design in term of
abluminal coating except novel fusion coating
(Fig. 1). Trend was similar (4.5%) among younger
group which proved its safety.
POCE in our study (9.5%) was consistant with
results using Orsiro [1], Biomatrix (9.2%) [2], Ultimaster (10.7%) [13], Supralimus Cruize (9.9%) [15],

FIREHAWK (19.3%), and Xience (17.8%) [16]. It was
remarkable despite higher proportion of complex
lesion, transfemoral intervention, CTO, and longer
mean length of stent. It was little higher than result
using sirolimus eluting stent (3.9%) by Youn et al.,
[18] because of higher proportion of transradial
intervention (79.1% vs. 22.6%) and lower proportion
of CTO (4.2% vs. 13.2%) compared to our study.
Stent thrombosis in our study was little higher
(1.7%) compared Orsiro (1.1%), Synergy (1.1%), and
Resolute Integrity (0.9%) [1], Ultimater (1.1%) [13],
and Supraﬂex Cruise (1.1%) [19] but similar to
FIREHAWK (1.7%) and lower than Xience (2.1%) [16]
and Biomatrix (2.4%). [17] Possible reasons could be
higher proportion of diabetes, small reference vessel
diameter, longer stent length, impaired left ventricular function, and small mean stent diameter in our
study. Although no signiﬁcant intergroup difference
were noted (1.3% vs. 1.9%), trend favoured younger
group as ST was lower in comparison to contempory
stents. Possible reasons for lower rate of late ST could
be reduced long-term inﬂammation as biodegradable polymer minimizes polymer volume.
Diffuse disease, CTO, and multiple lesions
sometimes may result into full metal jacketing (FMJ)
of vessel (total length of stents in single
vessel  60 mm) [19]. In their study of patients with
FMJ by Lee et al., TLF and ST were observed in 7%
and 1.2% respectively [19]. Similar observations
were noted in our study among patients who had

Fig. 4. ST over 12 months period of follow up between both group (A<35 years; B > 35 years).
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Fig. 5. KaplaneMeier survival curves of all patients over 12 months period of follow up.

Fig. 6. KaplaneMeier survival curves of patients over 12 months period of follow up between both group (A<35 years; B > 35 years).

330

JOURNAL OF THE SAUDI HEART ASSOCIATION 2021;XX:321e331

ORIGINAL ARTICLE

FMJ with no intergroup difference which showed
safety of Mitigator in this subgroup.
Incidence of in-stent restenosis (ISR) varies from
5e10% as a result of neointimal proliferation and
neoatherosclerosis [20]. DES was found to be the most
effective strategy for treating ISR in a meta-analysis
which compared conventional balloon angioplasty,
bare metal stents, DEB, brachytherapy, rotablation,
and DES (sirolimus, paclitaxel, everolimus) because
of lower risk of restenosis and need of repeat revascularization [2,3]. In our study, 2.2% patients had ISR
(signiﬁcantly higher in older age group) but their
outcome was comparable which indicated safety of
Mitigator among this subgroup. Fusion coating might
have contributing factor leading to uniform drug
delivery across the lesion and beyond.
In current generation stents, polymer-drug coating
is applied abluminally, luminally or uniformly on
both side (Fig. 1). Vascular smooth muscle cells which
grow in response to balloon/stent induced injury are
relatively resistant to sirolimus especially in diabetic
patients [4,5]. Mitigator stent ensures relatively
higher and uniform concentration of sirolimus which
lowers restenosis and TLF in this subgroup. Acute
gain in minimum luminal diameter is compensated
by late luminal loss (0.05e0.10 mm) as result of recoil
and intimal hyperplasia [5]. Because of ultrathin
design and biodegradable polymer, late luminal loss
does not impact signiﬁcantly on these smaller vessels
and in fact potential beneﬁt of these ultrathin-strut
stents are most pronounced in such vessels [21].

5. Conclusion
With availability of with longer stent ( 40 mm),
lower rate of TLF and repeat revascularization,
younger patients (< 35 years) can achieve complete
revascularization especially those with diabetes and
diffuse vessel disease.

6. Limitation
It was observational study with small sample size.
Moreover, patients with life expectancy < 12 months
and those presenting with cardiogenic shock were
excluded. Imaging modalities like IVUS and OCT
were not performed. Long term follow up (> 5 years)
would have provided further safety data. It was an
all comer study among real world patients which
typically negated potential drawback of randomized
control study.

Author contribution
Conception and design of Study: Santosh Kumar
Sinh, Umeshwar Pandey, Mahmodullah Razi,

Puneet Aggarwal, Mohit Sachan. Literature review:
Santosh Kumar Sinh, Umeshwar Pandey, Mahmodullah Razi. Acquisition of data: Santosh Kumar
Sinh, Umeshwar Pandey, Mahmodullah Razi, Mohit
Sachan. Analysis and interpretation of data: Santosh
Kumar Sinh, Umeshwar Pandey, Awadesh Kumar
Sharma, Praveen Shukla. Research investigation
and analysis: Awadesh Kumar Sharma, Puneet
Aggarwal, Praveen Shukla. Data collection: Awadesh Kumar Sharma, Puneet Aggarwal, Ramesh
Thakur. Drafting of manuscript: Mohit Sachan,
Praveen Shukla. Revising and editing the manuscript critically for important intellectual contents:
Praveen Shukla, Ramesh Thakur. Supervision of the
research: Ramesh Thakur.

Source of funding
None.

Conﬂict of interest
The authors certify that there is no conﬂict of interest with any ﬁnancial organization regarding
material discussed in the manuscript.

References
[1] Buiten RA, Ploumen EH, Zocca P, Doggen CJM, van der
Heijden LC, Kok MM, et al. Outcomes in patients treated with
thin-strut, very thin-strut, or ultrathin-strut drug-eluting
stents in small coronary vessels: a prespeciﬁed analysis of the
randomized BIO-RESORT trial. JAMA Cardiol 2019;4:659e69.
https://doi.org/10.1001/jamacardio.2019.1776.
[2] Giacoppo D, Alfonso F, Xu B, Claessen B, Adriaenssens CT,
Jensen C, et al. Drug-Coated balloon angioplasty versus
drug-eluting stent implantation in patients with coronary
stent restenosis. J Am Coll Cardiol 2020;75(21):2664e78.
https://doi.org/10.1016/j.jacc.2020.04.006.
[3] Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F,
Perez-Vizcayno MJ, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a
network meta-analysis. Lancet 2015;386:655e64. https://
doi.org/10.1016/S0140-6736(15)60657-2.
[4] Sojitra P, Doshi M, Galloni M, Vignolini C, Vyas A, Chevli B,
et al. Preclinical evaluation of a novel abluminal surface
coated sirolimus eluting stent with biodegradable polymer
matrix. Cardiovasc Diagn Ther 2015;5:254e63. https://
doi.org/10.3978/j.issn.2223-3652.2015.06.01.
[5] Asano T, Kobayashi Y, Fukushima K, Iwata Y, Kitahara H,
Ishio N, et al. Effect of balloon inﬂation time on expansion of
sirolimus-eluting stent. Heart Ves 2009;24:335e9. https://
doi.org/10.1007/s00380-008-1130-1.
[6] Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van
Es GA, et al. Clinical end points in coronary stent trials: a case
for standardized deﬁnitions. Circulation 2007;115:2344e51.
https://doi.org/10.1161/CIRCULATIONAHA.106.685313.
[7] Shah N, Kelly AM, Cox N, Wong C, Soon K. Myocardial
infarction in the ‘‘Young’’: risk factors, presentation, management and prognosis. Heart Lung Circ 2016;25:955e60.
https://doi.org/10.1016/j.hlc.2016.04.015.
[8] McGill Jr HC, McMahan CA, Zieske AW, Tracy RE,
Malcom GT, Herderick EE, et al. Association of coronary
heart disease risk factors with microscopic qualities of coronary atherosclerosis in youth. Circulation 2000;102:374e9.

[9] Christus T, Shukkur AM, Rashdan I, Koshy T, Alanbaei M,
Zubaid M, et al. Coronary artery disease in patients aged 35
or less - a different beast? Heart Views 2011;12:7e11. https://
doi.org/10.4103/1995-705X.81550.
[10] Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in
India. Heart 2008;94(1):16e26. https://doi.org/10.1136/
hrt.2007.132951.
[11] Prabhakaran D, Shah P, Chaturvedi V, Ramakrishnan L,
Manhapra A, Reddy KS. Cardiovascular risk factor prevalence among men in a large industry of northern India. Natl
Med J India 2005 Mar-Apr;18(2):59e65. PMID: 15981439.
[12] Meliga E, Benedictis MD, Gagnor A, Belli R, Scrocca I,
Lombardi P, et al. Long-term outcomes of percutaneous
coronary interventions with stent implantation in patients
<40 Years old. Am J Cardiol 2012;109:1717e21. https://
doi.org/10.1016/j.amjcard.2012.01.400.
[13] Wijns W, Valdes-Chavarri M, Richardt G, Moreno R,
I~
niguez-Romo A, Barbato E, et al. Long-term clinical outcomes after bioresorbable and permanent polymer drugeluting stent implantation: ﬁnal ﬁve-year results of the
CENTURY II randomised clinical trial. EuroIntervention
2018;14:e343e51. https://doi.org/10.4244/EIJ-D-18-00358.
[14] Windecker S, Serruys PW, Wandel S, Buszman P,
Trznadel S, Linke A, et al. Biolimus-eluting stent with
biodegradable polymer versus sirolimus-eluting stent with
durable polymer for coronary revascularisation (LEADERS):
a randomised non-inferiority trial. Lancet 2008;372(9644):
1163e73. https://doi.org/10.1016/S0140-6736(08)61244-1.
[15] Zaman A, de Winter RJ, Kogame N, Chang CC, Modolo R,
Spitzer E, et al. TALENT trial investigators. Safety and efﬁcacy of a
sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective

[16]

[17]

[18]

[19]

[20]

[21]

331

multicentre randomised controlled trial. Lancet 2019;393(10175):
987e97. https://doi.org/10.1016/S0140-6736(18)32467-X.
Lansky A, Wijns W, Xu B, Kelbæk H, van Royen N, Zheng M,
et al. Targeted therapy with a localised abluminal groove,
low-dose sirolimus-eluting, biodegradable polymer coronary
stent (TARGET All Comers): a multicentre, open-label,
randomised non-inferiority trial. Lancet 2018;392:1117e26.
https://doi.org/10.1016/S0140-6736(18)31649-0.
Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P,
Linke A, et al. Improved safety and reduction in stent
thrombosis associated with biodegradable polymer-based
biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease.
JACC Cardiovasc Interv 2013;6:777e89. https://doi.org/
10.1016/j.jcin.2013.04.011.
Youn YJ, Yoo SY, Lee JW, Ahn SG, Lee SH, Yoon J, et al.
Safety and efﬁcacy of a new ultrathin sirolimus-eluting stent
with abluminal biodegradable polymer in real-world practice. Korean Circ J 2020;50(4):317e27. https://doi.org/10.4070/
kcj.2019.0258.
Lee PH, Lee SW, Yun SC, Bae J, Ahn JM, Park DW, et al. Full
metal jacket with drug-eluting stents for coronary chronic
total occlusion. JACC Cardiovasc Interv 2017;10:1405e12.
https://doi.org/10.1016/j.jcin.2017.04.026.
Goel SS, Dilip Gajulapalli R, Athappan G, Philip F, Gupta S,
Murat Tuzcu E, et al. Management of drug eluting stent instent restenosis: a systematic review and meta-analysis.
Cathet Cardiovasc Interv 2016;87(6):1080e91. https://doi.org/
10.1002/ccd.26151.
Biondi-Zoccai G, Moretti C, Abbate A, Sheiban I. Percutaneous coronary intervention for small vessel coronary artery
disease. Cardiovasc Revascularization Med 2010;11(3):
189e98. https://doi.org/10.1016/j.carrev.2009.04.007.

ORIGINAL ARTICLE

JOURNAL OF THE SAUDI HEART ASSOCIATION 2021;XX:321e331

